Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Petite Pete on a Roll
View:
Post by Viking2233 on Jul 27, 2024 7:31pm

Petite Pete on a Roll

Now that you have replayed everything Arch has accomplished, which is impressive to say the least.

Pete, I have received a few private messages asking if you work for Arch. I have no idea if you do or not but you have clearly demonstrated what Arch has accomplished over the years.

Can you share with everyone any of the following:

1. How many patients have been dosed to date in Turkish trial?

2. Has a signal been observed in  the Turkish sites?

3. When will Canadian sites actually get final approvals and start dosing?

4. When will Pontiac Trial commence dosing?

5. Why is there a lack of interest or buyers in Arch with everything they have accomplished as you have outlined?

6. Why is there 0% institutional ownership in Arch with everything they have accomplished and where they are at?

7. Why is Arch share price 30% lower from 1 year ago?

8. Why is Arch market cap at $100M, yet dimilar dtaged peers are valued at $750M to $2B

9. Will Arch receive anymore government grants$

The above points are what modt are waiting for.
Comment by Renal22 on Jul 28, 2024 11:16am
RiverPetefolk 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities